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Abstract
 
Leishmania
 
 parasites are transmitted to their vertebrate hosts by infected phlebotomine sand fly
bites. Sand fly saliva is known to enhance 
 
Leishmania
 
 infection, while immunity to the saliva pro-
tects against infection as determined by coinoculation of parasites with vector salivary gland ho-
mogenates (SGHs) or by infected sand fly bites (Kamhawi, S., Y. Belkaid, G. Modi, E. Rowton,
and D. Sacks. 2000. 
 
Science.
 
 290:1351–1354). We have now characterized nine salivary proteins
of 
 
Phlebotomus papatasi
 
, the vector of 
 
Leishmania major
 
. One of these salivary proteins, extracted
from SDS gels and having an apparent mol wt of 15 kD, was able to protect vaccinated mice
challenged with parasites plus SGH. A DNA vaccine containing the cDNA for the predominant
15-kD protein (named SP15) provided this same protection. Protection lasted at least 3 mo after
immunization. The vaccine produced both intense humoral and delayed-type hypersensitivity
(DTH) reactions. B cell–deficient mice immunized with the SP15 plasmid vaccine successfully
controlled 
 
Leishmania
 
 infection when injected with 
 
Leishmania
 
 plus SGH. These results indicate
that DTH response against saliva provides most or all of the protective effects of this vaccine and
that salivary gland proteins or their cDNAs are viable vaccine targets against leishmaniasis.
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Introduction
 
The leishmaniases are a group of diseases caused by protozoa
 
of the genus 
 
Leishmania
 
 and affecting many millions of peo-
ple worldwide. In humans, it manifests either as a cutaneous
disease caused mainly by 
 
Leishmania major,
 
 
 
Leishmania tropica
 
,
and 
 
Leishmania mexicana
 
, as a mucocutaneous disease caused
mainly by 
 
Leishmania brasiliensis
 
, or as a visceral disease caused
mainly by 
 
Leishmania donovani
 
 and 
 
Leishmania chagasi
 
. All
leishmanial diseases are transmitted to their vertebrate hosts
by phlebotomine sand flies, which acquire the pathogen by
feeding on infected hosts and transmit them by regurgitating
the parasite at the site of a subsequent blood meal (1).
While obtaining a blood meal, sand flies salivate into the
host’s skin. This saliva contains anticlotting, antiplatelet,
and vasodilatory compounds that increase the hemorrhagic
pool where sand flies feed (2, 3). Some of these compo-
nents are additionally immunomodulatory. For example,
the New World sand fly 
 
Lutzomyia longipalpis
 
 contains the
6.5-kD peptide, maxadilan, which is the most potent va-
sodilator known (4). Maxadilan additionally has immuno-
suppressive activities of its own (5), as do many persistent
 
vasodilators such as prostaglandin E
 
2
 
 (6–8) and calcitonin
gene–related peptide (9). Old World sand flies (who share a
common ancestor with New World sand flies before the
separation of the present tectonic plates, or about the time
of irradiation of mammals) do not have maxadilan, but in-
stead use AMP and adenosine as vasodilators (10). Adeno-
sine is also an immunomodulatory component, promoting
 
the production of IL-10 and suppressing TNF-
 
 
 
 and IL-12
in mice (11–13). Additionally, 
 
Phlebotomus papatasi
 
 salivary
 
gland homogenate (SGH)
 
*
 
 as well as adenosine was shown
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to downregulate the nitric oxide synthase gene in activated
macrophages (14). Additionally, we previously reported
that SGH induced IL-4 at the site of inoculation in mice,
and that this effect was abrogated when IL-4 knockout
mice were used (15). Perhaps due to this immunomodula-
tory effect of saliva, coinjection of 
 
Leishmania
 
 with as little
as the equivalent of 0.25 pairs of vector SGH significantly
enhances 
 
Leishmania
 
 infectivity (16, 17). Conversely, im-
munity to SGH or previous exposure to sand flies prevents
leishmaniasis infectivity either by coinoculation of 
 
Leishma-
nia
 
 with SGH (15) or by infected sand fly bites (18).
Although enhancement of 
 
Leishmania
 
 infectivity by SGH
is probably due to the immunomodulatory components of
sand fly saliva, explanation of the anti-
 
Leishmania
 
 effect re-
sulting from host immunization against salivary antigens is
not straightforward. We previously suggested that the exac-
erbating effect of SGH was mediated by an early release of
IL-4 at the inoculation site (15). Mice preexposed to SGH
were protected against this early burst of IL-4 and from the
exacerbatory effect of the saliva. Immunity in this system
could be derived from neutralization by antibodies of yet
nonidentified 
 
P. papatasi
 
 salivary immunomodulator(s). Al-
ternatively, immunity could derive from a delayed-type
hypersensitivity (DTH) reaction at the site of the bite gen-
erated by a cellular response to salivary antigens injected by
the fly (18, 19). This particular reaction could turn the
feeding lesion and its surroundings into an inhospitable site
for the establishment of 
 
Leishmania
 
 into the new host or al-
ter the milieu priming the initial events of the host immune
reaction to 
 
Leishmania
 
 (19). In a natural challenge model,
mice preexposed to the bite of sand flies showed a signifi-
cant increase of the release of IL-12 and IFN-
 
 
 
 at the site
of the bite compared with naive mice (18). Although the
two possibilities (antibodies and DTH) are not mutually
exclusive, the first explanation cannot justify why previous
exposure to 
 
P. papatasi 
 
SGH or bites confer immunity to 
 
L.
major
 
 (17) if we consider that adenosine is the main immu-
nosuppressor in 
 
P. papatasi
 
 saliva. Each of the theories re-
 
quires distinct strategies for vaccine development: the
immunomodulatory neutralization theory requires identifi-
cation of the immunomodulator and its modification into
an appropriate immunogen, while the DTH theory will
make any protein in the saliva a fair target. We report here
the complete sequence of nine major salivary proteins from
the sand fly vector of 
 
L. major
 
, 
 
P. papatasi
 
, identify a candi-
date antigen that confers protection against 
 
L. major
 
 trans-
mission in mice when coinjected with SGH, and investi-
gate the role of antibodies and DTH in this vaccine model.
 
Materials and Methods
 
Sand Flies and Preparation of SGH.
 
P. papatasi
 
, Israeli strain,
were reared at the Walter Reed Army Medical Research Insti-
tute, using as larval food a mixture of fermented rabbit feces and
rabbit food (20). Adult sand flies were offered a cotton swab con-
taining 20% sucrose and were used for dissection of salivary
glands at 2–7 d after emergence. Salivary glands were stored in
 
groups of 20 pairs in 20 
 
 
 
l NaCl (150 mM) Hepes buffer (10
mM, pH 7.4). Salivary glands were disrupted by ultrasonication
within 1.5-ml conical tubes. Tubes were centrifuged at 10,000 
 
g
 
for 2 min and the resultant supernatant used for the studies.
 
Mice.
 
C57BL/6 mice were purchased from the Division
of Cancer Treatment, National Cancer Institute. C56Bl/10
 
 
 
MTKO (B cell–deficient [B
 
 
 
/
 
 
 
]) mice were obtained from
Taconic Farms. Mice were maintained in the National Institute
of Allergy and Infectious Diseases Animal Care Facility under
pathogen-free conditions.
 
SDS-PAGE.
 
Tris-glycine gels (16%), 1-mm thick, were
used (Invitrogen). Gels were run with Tris-glycine buffer accord-
ing to the manufacturer’s instructions. To estimate the mol wt of
the samples, SeeBlue™ markers from Invitrogen (myosin, BSA,
glutamic dehydrogenase, alcohol dehydrogenase, carbonic anhy-
drase, myoglobin, lysozyme, aprotinin, and insulin, chain B) were
used. SGH were treated with equal parts of 2
 
 
 
 SDS sample
buffer (8% SDS in Tris-HCl buffer, 0.5 M, pH 6.8, 10% glycerol,
and 1% bromophenol blue dye). 30 pairs of homogenized salivary
 
glands per lane (
 
 
 
30 
 
 
 
g protein) were applied when visualization
of the proteins bands stained with Coomassie blue was desired.
For NH
 
2
 
-terminal sequencing of the salivary proteins, 40 homog-
enized pairs of glands were electrophoresed and transferred to
 
polyvinylidene difluoride (PVDF) membrane using 10 mM 3-[cy-
clohexylamino]-1-propane-sulfonic acid (CAPS), pH 11, 10%
methanol as the transfer buffer on a Blot-Module for the XCell II
Mini-Cell (Invitrogen). The membrane was stained with Coo-
massie blue in the absence of acetic acid. Stained bands were cut
from the PVDF membrane and subjected to Edman degradation
using a Procise sequencer (PerkinElmer).
 
Western Blot Analysis.
 
SDS-PAGE of 
 
P. papatasi
 
 SGH (50 sal-
ivary gland pairs) for Western blot analysis was done on 16% Tris-
glycine gel containing a single long well (Invitrogen). After elec-
trophoresis, salivary proteins were transferred to a nitrocellulose
membrane using Tris-glycine buffer with 10% methanol as the
transfer buffer on a Blot-Module for the XCell II Mini-Cell. The
 
nitrocellulose membrane was then incubated overnight at 4
 
 
 
C
with blocking buffer (Tris pH 8.0 plus 150 mM NaCl plus 5%
non-fat milk). After the blocking step, the membrane was placed
on a Mini-protean II multiscreen apparatus (Bio-Rad Laborato-
ries) that allows testing of 16 different serum samples from a single
blot. Sera from mice preexposed to SGH, from mice bitten by
sand flies or from naive mice, were diluted 1:200 with blocking
buffer and added individually to various channels on the multi-
screen apparatus. The membrane was incubated with the different
serum samples for 2 h at room temperature. Serum samples were
removed from the channels of the multiscreen apparatus and
washing buffer (Tris pH 8.0 plus 150 mM NaCl plus 0.1% Tween
20) was added three times. The membrane was then removed
from the multiscreen device and washed again three times, 5 min
per wash, with washing buffer. The membrane was then incu-
bated with a 1:10,000 dilution of an anti–mouse IgG alkaline
phosphatase–conjugated antibody for 1 h at room temperature.
The membrane was washed three times with washing buffer as
described above. Positive bands were visualized by adding alkaline
phosphatase substrate (Promega) and the reaction stopped by
washing the membrane three times with deionized water.
 
Salivary Gland cDNA Library Construction. P. papatasi
 
 salivary
gland mRNA was isolated from 85 salivary gland pairs from adult
females at days 1, 2, and 3 after emergence. Library construction
was completed exactly as described previously (21).
 
Massive Sequencing of P. papatasi Salivary Gland cDNA Library.
 
The 
 
P. papatasi
 
 salivary gland cDNA library was plated to 
 
 
 
200
plaques/plate (150-mm Petri dish). These procedures were also 
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completed as described previously (21).
 
DNA Vaccine Construction and Description of the VR1020
Vector.
 
The gene coding for SP15 (from NH
 
2
 
 terminus to stop
codon) was amplified from 
 
P. papatasi
 
 SP15-specific cDNA by
PCR using High-Fidelity platinum 
 
Taq
 
 polymerase (GIBCO
BRL) and specific primers carrying BamHI restriction sites
(forward SP15BHF 5
 
 
 
-TGCGGATCCGAAAATCCATCAAA-
GAAG-3
 
 
 
; reverse SP15BHR 5
 
 
 
-ATTGGATCCTTATATAT-
TGATTGTTTT-3
 
 
 
). The PCR product was immediately
cloned into the TOPO TA cloning vector PCRII (Invitrogen)
following the manufacturer’s specifications. The ligation mixture
was used to transform TOP10 cells (Invitrogen) and the cells
were incubated overnight at 37
 
 
 
C. Eight colonies were picked
and mixed with 10 
 
 
 
l of sterile water. 5 
 
 
 
l of each sample were
transferred to Luria broth with ampicillin (100 
 
 
 
g/ml) and grown
at 37
 
 
 
C. The other 5 
 
 
 
l were used as a template for a PCR reac-
tion using two vector-specific primers from the PCRII vector to
confirm the presence of the insert and for sequencing analysis. Af-
ter visualization of the PCR product on a 1.1% agarose gel, we
completely sequenced the eight PCR products as described above
using a CEQ2000 DNA sequencing instrument (Beckman
Coulter). We chose a sample that contained the sequence from
the NH
 
2
 
 terminus to stop codon of the SP15 gene including the
incorporated BamHI sites. Cells containing the plasmid carrying
the SP15 gene were grown overnight at 37
 
 
 
C on Luria broth
with ampicillin (100 
 
 
 
g/ml), and plasmid isolation was per-
formed using the Wizard Miniprep kit (Promega). The plasmid
containing the SP15 gene with incorporated BamHI sites was di-
gested with BamHI and then ligated with the BamHI predigested
VR1020 DNA plasmid vector (VICAL). The VR1020 plasmid
contains a kanamycin resistance gene, the human cytomegalovi-
rus promoter, and the tissue plasminogen activator signal peptide
upstream of the BamHI cloning site. The ligation reaction be-
tween the BamHI digested SP15 gene and the similarly digested
VR1020 DNA vector was done overnight at 16
 
 
 
C to transform
TOP10 cells (Invitrogen). Cells were incubated on a Luria broth
kanamycin (30 
 
 
 
g/ml) plate overnight at 37
 
 
 
C. 32 colonies were
picked and mixed with 10 
 
 
 
l of sterile water. 5 
 
 
 
l of each sample
were transferred to Luria broth with kanamycin (100 
 
 
 
g/ml) and
grown at 37
 
 
 
C. The other 5 
 
 
 
l were used as a template for a
PCR reaction using two vector-specific primers from the
VR1020 vector to confirm the presence of the insert and for se-
quencing analysis. After visualization of the PCR product on a
1.1% agarose gel, we proceeded to sequence completely four
PCR products as described above using a CEQ2000 DNA se-
quencing instrument (Beckman Coulter). For the vaccine con-
struct, we chose a sample that contained the sequence from the
NH
 
2
 
 terminus to the stop codon in the right orientation and in
the correct open-reading frame after the tissue plasminogen acti-
vator signal peptide. Cells containing the SP15 gene on VR1020
were grown overnight at 37
 
 
 
C on Luria broth with kanamycin
(100 
 
 
 
g/ml) and plasmid isolation was performed using the Wiz-
ard Miniprep kit. After plasmid isolation, the sample and control
plasmids (VR1020 alone) were washed three times with ultrapure
water using an Amicon-100 (Millipore). The concentrations of
the samples were measured by UV absorbance, and they were
stored at 
 
 
 
70
 
 
 
C before immunization experiments.
 
DNA and Predicted Protein Sequence Analysis.
 
DNA data de-
rived from the mass sequencing project were analyzed by an in-
house program written in VisualBASIC (Microsoft). This pro-
gram removed vector and primer sequences from the raw
sequence. Stripped sequences were compared with the NCBI non-
redundant protein database using the program BlastX using the
 
BLOSUM-62 matrix (22). DNA sequences were clustered by
blasting the database against itself with a preselected threshold
cutoff, usually 10
 
–10
 
 (BlastN program) (22). Sequences from the
same cluster were aligned using ClustalX (23). To find the cDNA
sequences corresponding to the amino acid sequence obtained by
Edman degradation of the proteins transferred to PVDF mem-
branes from PAGE gels, we wrote a search program that checked
these amino acid sequences against the three possible protein
translations of each cDNA sequence obtained in the mass se-
quencing project. This was written using the same approach used
in the BLOCKS (24) or Prosite (25) programs. Protein transla-
tions of the full-length clones were further processed to identify
the predicted signal peptides using the Signal P program (26),
available at http://genome.cbs.dtu.dk/services/SignalP/. Pre-
dicted signal peptide cleaved sites were compared with the NH
 
2
 
terminus sequence obtained from Edman degradation of 
 
P. pap-
atasi
 
 salivary proteins. Estimation of isoelectric point and mol wt
of translated protein was performed using the DNA STAR pro-
gram (DNASTAR, Inc.). Full-length translated protein sequence
information was compared with the nonredundant protein data-
base of NCBI using the BLAST-P program (22) and searched for
motifs by submitting each sequence to http://www.motif.
genome.ad.jp/.
 
Parasite Preparation and Intradermal Inoculation. L.  major
 
 clone
V1 (MHOM/IL/80/Friedlin) was cultured in 199 medium with
20% heat-inactivated fetal bovine serum (HyClone), 100 U/ml
penicillin, 100 
 
 
 
g/ml streptomycin, 2 mM 
 
l
 
-glutamine, 40 mM
Hepes, 0.1 mM adenine (in 50 mM Hepes), 5 mg/ml hemin (in
50% triethanolamine), and 1 mg/ml 6-biotin (M199/S). Infec-
tive-stage metacyclic promastigotes of 
 
L. major
 
 were isolated from
stationary cultures (4–5 d old) by negative selection using peanut
agglutinin (Vector Laboratories). 500 metacyclic promastigotes
with or without 0.5 pair of SGH were inoculated intradermally
into the left ear dermis using a 27-gauge needle in a volume of
 5  l. The evolution of the lesion was monitored by measuring
the diameter of the induration of the ear lesion with a direct-
reading Vernier caliper (Thomas Scientific). Parasite titrations
were performed as described previously (17, 27).
Vaccination. SGH (30 salivary gland pairs) was separated by
SDS-PAGE and stained with Coomassie blue as described above.
The gel was divided into three groups containing proteins in the
range of 200 to 50 kD (fraction A,  11  g), from 49 to 20 kD
(fraction B,  9  g), and below 20 kD (fraction C,  10  g). A
control piece of acrylamide from the gel was used (fraction E).
The gel was cut and transferred to a 1.5-ml tube and washed
three times with sterile PBS (pH 6.8) plus 150 mM NaCl. The
bands were then triturated using a plastic pestle until the prepara-
tion could be resuspended in 500  l of sterile phosphate-saline
buffer using a 27-gauge needle to give a solution of  0.02  g/
 l. Immunization with SDS-PAGE fractions was performed by
the injection of 10  l of either fraction A, B, C, or E into the
right ear of each mouse, followed by a boost 2 wk later. For ge-
netic immunization, mice were inoculated in the right ear with
5–10   g of the plasmid encoding for SP15 or control DNA
(empty vector) suspended in 5  l of PBS. Each group was
boosted 2 wk later using the same regimen. Mice were bled and
the presence of antibodies assessed for each individual mouse by
Western blot as described above.
Analysis of the Inflammatory Response in the Ear Dermis. The left
ears of mice vaccinated (in the right ear) or not with the plasmid
vector were exposed to the bite of sand flies as described previ-
ously (19). 24 h after the sand fly exposure, seven mice per group
were killed and the left ear collected. Each ear was processed in-334 Toward a Defined Anti-Leishmania Vaccine Targeting Vector Salivary Antigens
dividually. The cells in the inflammatory ear dermis were recov-
ered as described previously (15).
Immunolabeling for Flow Cytometry Analysis. The dermal cells
were incubated with 10% normal mouse serum in PBS contain-
ing 0.1% BSA, 0.01% NaN3 before being incubated with anti-Fc
receptor antibody (2.4G2; BD PharMingen). The double staining
was done by using directly conjugated antibodies incubated si-
multaneously. The dermal inflammatory cells were identified by
characteristic size forward scatter (FSC) and granulosity side scat-
ter (SSC) combined with two-color analysis, as described previ-
ously (28).
Statistical Analysis. Statistical tests were performed with Sig-
maStat (Jandel Software). Because most comparisons derived
from data with nonhomogeneous variances, Kruskal-Wallis anal-
ysis of variance (ANOVA) on ranks was performed and multiple
comparisons were done by the Dunn method. Dual comparisons
were made with the Mann-Whitney rank sum test. All data from
parasite numbers were log transformed before conducting statisti-
cal tests.
Results
The salivary gland of P. papatasi is a sac-like structure
consisting of a unicellular epithelium layer surrounding a
large lumen (29). After a blood meal, the gland total pro-
tein content decreases to half or less from its  1  g value
(30). Accordingly, most of the protein from the fly SGH
must be destined for secretion. Indeed, SDS-PAGE of
SGH reveals a low complexity composition consisting of
 12 major bands varying from 10–100 kD (Fig. 1 A). Sera
from individual mice inoculated with SGH or exposed to
sand fly bites recognized antigens that colocalized with one
or more of these major bands when detected by Western
blot assays (Fig. 1 B). Nonexposed controls or preimmune
sera did not react to P. papatasi salivary antigens (Fig. 1 B).
To characterize the primary structure of the main pro-
teins of P. papatasi SGH, we transferred SDS-PAGE gels
to PVDF membranes, and estimated the NH2-terminal
sequence of each cut band by Edman degradation. Of
12 bands, with the exception of one that is probably
blocked by a pyroglutamyl residue (NH2-terminal sequence
QXXX), 11 bands yielded information as shown in Fig. 2.
The NH2-terminal sequences were used to screen a 3-frame
translation of a cDNA database originating from  600
DNA sequences obtained from randomly picked clones
from a unidirectionally cloned salivary gland cDNA library
from P. papatasi. Matching clones were subsequently fully
sequenced using custom primers. The proteins in Fig. 2 are
named according to their mobility in nonreducing SDS-
PAGE. A brief description of the clones is enclosed in Table
I, with their NCBI accession nos., best match to the NCBI
NR protein database, predicted mol wt, and motifs found.
All proteins had a predicted signal secretory sequence (26),
and their site of cleavage was confirmed by Edman degrada-
tion. All proteins were basic, with a pI ranging from 8.28 to
9.43. Note that we obtained the same NH2-terminal se-
quence for two SDS-PAGE bands, located at 32 and 64 kD;
we presume the heavier is a homodimer. Additionally, the
same NH2-terminal sequence was obtained from the SDS-
PAGE bands located at 42 and 46 kD, the difference possi-
bly arising from posttranslation modification.
SGH of P. papatasi is known to enhance infection of L.
major when injected in naive mice (16, 17). Previous im-
munization of mice with SGH or by exposure to nonin-
fected sand flies not only prevents the enhancing effect of
SGH but also actually protects mice from Leishmania when
coinoculated with saliva or by bites of infected sand flies
(15, 18). To investigate which fractions from saliva produce
the most effective protection when mice are subsequently
challenged with parasites and SGH, we separated SGH by
SDS-PAGE, divided the gel into three groups containing
proteins in the range of 200 to 40 kD, from 39 to 20 kD,
and below 20 kD. A control group receiving gel without
proteins was also run, together with noninjected controls.
After intradermal immunization in the ear, mice were chal-
lenged in the contralateral ear with parasites and SGH. As
shown before, naive mice inoculated with SGH plus para-
sites had significantly increased lesion size at 5.5 wk postin-
oculation, when compared with naive mice inoculated
with parasites only. Mice vaccinated intradermally with the
lower mol wt fractions (fraction C), and challenged with
both parasites and SGH had the best protection in this assay
(Fig. 3 A; P   0.05). Parasite load at 4.5 wk postinocula-
tion were also lower in fraction C–vaccinated mice (P  
0.05; Fig. 3 B). A strong antibody response was obtained
when mice were inoculated with the smaller protein size
region of the gel (Fig. 4). Within this group, a stronger re-
action was mounted against an antigen identical to or
comigrating with a protein of 15 kD, here named SP15
protein (PpSP15), as identified in Fig. 2 and Table I.
To test the role of the SP15 gel region in conferring re-
sistance to leishmaniasis in mice, we vaccinated mice with
the SP15 band obtained from SDS-PAGE or with an acryl-
amide control injection and challenged these animals with
Figure 1. SDS-PAGE and Western blots of SGH of P. papatasi. (A)
Coomassie blue–stained PVDF membrane after gel transfer of 40 ho-
mogenized pairs of glands. The numbers represent the position of the mol
wt markers. (B) Western blots of the gels with mouse sera obtained from
mice immunized by intradermal inoculation of SGH (needle inoculation)
or the bite of uninfected sand flies (sand fly bite) with their preimmuniza-
tion (PI) controls.335 Valenzuela et al.
Figure 2. SDS-PAGE of 20 homogenized
pairs of salivary glands from P. papatasi. Left
side of figure, indication of the NH2-termi-
nal sequence found for each band by Edman
degradation; right side of figure, clone identi-
fication name. Numbers indicate the position
of the mol wt marker in the same gel.
Table I. Salivary Proteins from Phlebotomus papatasi
Salivary proteina
(accession number) NCBI best matchb
kDc
(predicted)
Motifsd
(http://www.motif.genome.ad.jp/)
PpSP64
(AF335490)
Flagelliform silk protein, (Nephila clavipes),
(AF027972), E   0.043
24.4 (PROSITE)
ATP/GTP binding motif (GNVDSGKT)
PpSP52 N.D. N.D. N.D.
PpSP46
(AF335491)
Yellow protein, (Lutzomyia longipalpis),
(AF132518), E   10 97 44.4
(PRODOM)
Protein major royal jelly, bee-milk glycoprotein, yellow
PpSP44
(AF335492)
Yellow protein, (Lutzomyia longipalpis),
(AF132518), E   10 101
43.6 (PRODOM)
Protein major royal jelly, bee-milk glycoprotein, yellow
(PRINTS)
Rhosospin-like GPCR superfamily signature
PpSP42
(AF335491)
Yellow protein, (Lutzomyia longipalpis),
(AF132518), E   10 97
44.4 (PRODOM)
Protein major royal jelly, bee-milk glycoprotein, yellow
PpSP36
(AF261768)
Salivary apyrase, (Phlebotomus papatasi),
(AF261768)
35.8 (PRINTS)
Rhosospin-like GPCR superfamily signature
PpSP32
(AF335490)
Flagelliform silk protein, (Nephila clavipes),
(AF027972), E   0.043
24.4 (PROSITE)
ATP/GTP binding motif (GNVDSGKT)
PpSP30
(AF335489)
D7 protein, (Aedes aegypti),
(P18153), E   10 05
27.8 (PRINTS)
transforming protein P21 RAS signature
PpSP28
(AF335488)
D7 protein, (Aedes aegypti),
(P18153), E   20 05
27.2 (PRINTS)
Rhosospin-like GPCR superfamily signature
PpSP15
(AF335487)
SL1 protein, (Lutzomyia longipalpis),
(AF132517), E   60 12
14.5 (PRINTS)
Rhosospin-like GPCR superfamily signature
PpSP14
(AF335486)
SL1 protein, (Lutzomyia longipalpis),
(AF132517), E   10 18
14.7 None
PpSP12
(AF335485)
SL1 protein, (Lutzomyia longipalpis),
(AF132517), E   20 13
13.8 None
aName and NCBI accession number for salivary protein cDNA.
bBest match of the salivary protein to the NR protein database from NCBI, as accessed by Blast-P program.
cPredicted molecular weight of the mature protein.
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L. major in the presence and absence of SGH. Results indi-
cated that vaccination with the SP15 band greatly affected
disease manifestation as measured by lesion size, which
were significantly smaller (P   0.05) than those of mice
vaccinated but not receiving SGH at the time of Leishmania
inoculation or of acrylamide-vaccinated mice receiving
parasites plus SGH (Fig. 5 A). The parasite load at 9-wk
postinoculation was smaller on the SP15-vaccinated mice
challenged with parasites and SGH, but only borderline so
(P   0.056) when compared with the acrylamide-vacci-
nated controls (Fig. 5 B).
To further confirm whether immunity against SP15
could protect mice when parasites are coinjected with
SGH, we constructed a DNA vaccine using the P. papatasi
salivary SP15 gene. The SP15 cDNA is 522 bp in length
and codes for a protein of 142 amino acids including the
signal peptide. The mature protein, as predicted by the Sig-
nal P program and confirmed by Edman degradation, has
14,494.81 dalton. Accordingly, the SP15 gene coding for
the mature protein was inserted downstream and in frame
with the signal peptide of tissue plasminogen activator
present in the VR1020 vector. This construct is named
SP15-Pl. Control plasmids, consisting of VR1020 plasmid
alone, were used to immunize control mice. This control
plasmid is named CTL-Pl. Mice immunized with SP15-Pl,
but not those immunized with the CTL-Pl, produced anti-
bodies recognizing a single band in Western blots of SGH,
at the position of SP15 in the gel (Fig. 6 A). Additionally,
to determine whether the SP15 vaccination would induce
a DTH response in mice after the bite of uninfected sand
flies, we exposed naive, SP15-Pl–immunized, and plasmid
control–immunized mice to sand fly bites. Results indicate
that mice vaccinated with SP15-Pl developed an intense
DTH response 24 h after exposure to sand flies (Fig. 6 B),
comparable to the DTH observed after saliva inoculation in
sensitized mice (data not shown) and as shown previously
(18). This reaction is characterized by swelling and a mas-
sive cell infiltrate consisting primarily of neutrophils, eo-
sinophils, and macrophages (Fig. 6 B). This experiment indi-
cates that the plasmid vaccine is producing both serum and
cellular immunity reactions.
We investigated the effects of immunization with SP15-
Pl on the development of L. major infection coinjected or
not with SGH. The intradermal coinoculation of 500 L.
major with 0.5 pair of SGH had a dramatic effect on the pa-
thology in naive mice or mice vaccinated with CTL-Pl,
consistent with previous results (15, 18; Fig. 7). The lesions
developed more rapidly and presented an ulcerative pathol-
ogy compared with controls inoculated without saliva. In
contrast, mice previously vaccinated with SP15-Pl and
challenged with parasite plus SGH developed a minor and
nonulcerative pathology. The lesions were significantly
smaller not only compared with controls (naive or CTL-Pl)
inoculated with saliva but also compared with mice inocu-
lated with the parasite alone (data not shown). The indura-
Figure 3. Effect of mouse immunization with fractions of SGH sepa-
rated by SDS-PAGE. Effect on (A) the lesion size and (B) the number of
parasites 4.5 wk postchallenge after L. major infection. Naive mice were
inoculated intradermally with 500 L. major promastigotes alone ( ) or in
the presence of 0.5 pairs of SGH ( ). Mice previously vaccinated on the
right ear (2-wk intervals) with acrylamide alone, E ( ) or mol wt range
from 200 to 40 kD, A ( ); 39 to 20 kD, B ( ); or 19 to 3 kD, C ( )
were challenged in the left ear 2 wk after the last immunization with 500
L. major promastigote in the presence of 0.5 pairs of SGH. The above
symbols and bars represent the mean induration in mm   SE (five mice
per group) or the mean number of parasite per ear   SE (four mice per
group). (*) indicate significance at P   0.05 when treatment curve (C)
was compared with the acrylamide control (E).
Figure 4. Western blots of SGH of P. papatasi reacted with sera from
mice immunized with polyacrylamide fractions separating the SGH by
SDS-PAGE. Divisions were a high (A), medium (B), and low (C) mol wt
region, as detailed in the legend to Fig. 3, or from control mice immu-
nized with polyacrylamide (E), as shown.337 Valenzuela et al.
tion in the SP15-Pl–vaccinated mice resolved as early as 6
wk postchallenge, while in the CTL-Pl–immunized mice
inoculated with saliva, the large ulcerative, necrotic lesions
were maintained. Similarly, the intradermal coinoculation
of 500 L. major with 0.5 pair of SGH enhanced the parasite
load in naive and CTL-Pl vaccinated C57BL/6 mice com-
pared with their respective controls, inoculated with the
parasite alone (Fig. 7).
To evaluate the persistence of the immunity induced by
the DNA vaccine, the animals were challenged or not
with SGH 12 wk, rather than 2 wk, after the last boosting.
The protection was comparable to that achieved when the
challenge was performed 2 wk postvaccination, with a sig-
nificant reduction of both lesion size and parasite number
(Fig. 8).
Having shown that immunization with SP15-Pl induces
both antibody and DTH (Fig. 6) responses, we evaluated
the contribution of antibodies versus cellular immunity in
the anti-Leishmania protective effect. B /  mice were im-
munized with SP15-Pl and CTL-Pl with the expectation
that this model animal would provide only a cellular re-
sponse to SP15. Indeed, similarly to the wild-type (wt)
controls, only B /  mice vaccinated with SP15-Pl devel-
oped an intense DTH response when challenged with 500
L. major promastigotes in the presence of 0.5 pairs of SGH
(Fig. 9 B). As expected, no antibodies from the B /  mice
were detected by Western blots (Fig. 9 A), although anti-
bodies were produced by the control wt mice (B10 mice).
When challenged with parasites and SGH, vaccinated B / 
mice had significantly lower pathology at 5.5 wk postinoc-
ulation than did mice vaccinated with the control plasmid
(P   0.008; Fig. 10 A). When compared with the CTL-
Figure 5. Effect of mouse immunization with band SP15 from SDS-
PAGE gels separating the SGH of P. papatasi on the lesion size (A) and
the number of parasites 9 wk postchallenge (B) after L. major infection.
Naive mice were inoculated intradermally with 500 L. major promasti-
gotes alone ( ) or in the presence of 0.5 pairs of SGH ( ). Mice previ-
ously vaccinated on the right ear (2-wk intervals) with acrylamide alone,
E ( ) or band SP15 ( ) were challenged in the left ear 2 wk after the last
immunization with 500 L. major promastigotes in the presence of 0.5 pairs
of SGH. The above symbols and bars represent mean induration in mm  
SE (five mice per group) or mean number of parasites per ear   SE (five
mice per group). (*) indicate significance at P   0.05 when the treatment
curve was compared with the acrylamide control.
Figure 6. Mouse humoral and cellular immunities are generated by in-
jection of the VR1020 plasmid containing the SP15 sequence (SP15-Pl).
(A) Western blots of salivary homogenates of P. papatasi reacted against
sera of mice immunized twice in the right ear (2-wk interval) with 5  g
of the SP15-Pl or control VR1020 plasmid (CTL-Pl). (B) DTH reaction
induced by sand fly bites on mice vaccinated with SP15-Pl. The left ears
of naive mice, mice immunized with SP15-Pl, or control CTL-Pl mice
were exposed to the bite of 10 sand flies. 24 h later, the mice were killed,
and the inflammatory cells (neutrophils, eosinophils, macrophages, den-
dritic cells, CD4 , and CD8  T cells) present in the dermis were ana-
lyzed. The symbols and bars represent the mean number of cellular sub-
sets per ear   SE; seven mice per group.338 Toward a Defined Anti-Leishmania Vaccine Targeting Vector Salivary Antigens
Pl–vaccinated mice (P   0.05), parasite loads at 5.5 wk
postinoculation were significantly lower in mice vaccinated
with SP15-Pl and inoculated with parasites plus SGH, irre-
spective of whether the mice were B cell deficient (Fig. 10
B). Comparisons of the parasite loads between B /  and wt
mice indicated that B /  mice had smaller parasite loads
than the wt controls (P   0.006).
Discussion
Having proposed that immunity to sand fly saliva may
confer protection to subsequent Leishmania infection (15,
18), we proceeded to (a) characterize the main proteins in
the salivary glands of the sand fly P. papatasi that may serve
as antigens; (b) identify a protein band from SDS-PAGE
that was effective in providing protection against coinocu-
lation of L. major plus SGH; (c) construct a DNA vaccine
containing the coding information of the main protein co-
eluting with the gel band described in b; and (d) character-
ize the role of cell-mediated immunity in the action of the
DNA vaccine.
Two strategies are possible in selecting vaccine candi-
dates from the salivary glands of sand flies. It is known that
sand fly SGH enhances Leishmania transmission when coin-
oculated with parasites in naive mice but not in mice vacci-
nated with SGH or pre-exposed to sand fly bites (16–18). It
is also known that sand fly saliva has immunomodulatory
components (5, 14). In particular, P. papatasi SGH induce
the release of IL-4 at the site of inoculation (15). If one
considers that the effect of saliva in enhancing Leishmania
infection is due to these immunomodulatory substances,
then salivary gland–induced immunity could be due to the
neutralization of such compounds. For example, in a previ-
ous work, the release of IL-4 was neutralized by antibodies
against SGH in presensitized mice, a result correlating with
protection against infection (15). Alternatively, immunity
against any salivary antigen could modify the site of parasite
inoculation in a manner that would disrupt successful para-
site transmission. For example, in a sand fly challenge ex-
periment, the level of IFN-  and IL-12 was significantly
increased in the mouse skin after sand fly reexposure (18).
While the first hypothesis limits the vaccine candidates to
the immunomodulatory salivary components, the second
makes all salivary proteins possible vaccine targets.
Whereas SGH of New World sand flies of the genus
Lutzomyia contain the vasodilatory and immunomodula-
tory peptide maxadilan (4, 5), Old World sand flies of the
genus Phlebotomus have adenosine and AMP as their main
vasodilator (10), and lack maxadilan. Studies in progress in
our laboratory indicate that a mixture of adenosine and
AMP is as powerful in enhancing Leishmania infection as
SGH of P. papatasi (unpublished data). Adenosine, but not
maxadilan, was also shown to inhibit nitric oxide expres-
Figure 7. Effect of mouse immunization with SP15-Pl on the lesion
size caused by L. major infection. Naive mice were inoculated intrader-
mally with 500 L. major promastigotes alone ( ) or in the presence of 0.5
pairs of SGH ( ). Mice previously vaccinated on the right ear (2-wk in-
tervals) with SP15-Pl ( ,  ) or CTL-Pl ( ,  ) were challenged in the
left ear 2 wk after the last immunization with 500 L. major promastigotes
in the presence ( ,  ) or not ( ,  ) of 0.5 pairs of SGH. The symbols
and bars represent the mean induration in mm   1 SE; five mice per
group. (*) indicate significance at P   0.05 when the treatment curve was
compared with the control (CTL-Pl   SGH).
Figure 8. Long-term effect of mouse immunization with SP15-Pl on
L. major infection. (A) Effect on lesion size. Naive mice were inoculated
intradermally with 500 L. major promastigotes alone ( ) or in the pres-
ence of 0.5 pairs of SGH ( ). Mice previously vaccinated on the right ear
(2-wk intervals) with SP15-Pl ( ,  ) or CTL-Pl ( ,  ) were challenged
in the left ear 12 wk after the last immunization with 500 L. major pro-
mastigotes in the presence ( ,  ) or not ( ,  ) of 0.5 pairs of SGH. (B)
Effect on parasite number at 6.5 wk postchallenge. The symbols and bars
represent the mean induration in mm   1 SE; five mice per group. (*) in-
dicate significance at P   0.05 when the treatment curve was compared
with the control (CTL-Pl   SGH).339 Valenzuela et al.
sion in activated macrophages (14). Because exposure to P.
papatasi bites or to needle inoculation of P. papatasi SGH
confer protection to subsequent inoculation of parasites
plus SGH (15, 18), we hypothesize that this immunity is
not due to neutralization of salivary immunomodulators—
such as adenosine—but rather to the modification of the
parasite inoculation site due to a cell-mediated reaction
with salivary gland antigens. Accordingly, any salivary
gland protein is a potential vaccine candidate to Phleboto-
mus-transmitted Leishmania.
A combination of random sequencing of a salivary gland
cDNA library with NH2-terminal sequencing of salivary
gland proteins separated by unidimensional SDS-PAGE
and transferred to PVDF membranes led to identification
and full primary sequence characterization of the major-
ity of the proteins visible by Coomassie blue staining of
the gels. Except for the apyrase enzyme (PpSP36; refer-
ence 21), all identified proteins have unknown function.
PpSP12, PpSP14, and PpSP15 are similar to a protein (SL1)
present in the saliva of L. longipalpis. PpSP28 and PpSP30
belong to the odorant-binding superfamily (31) and may
have a function in binding pharmacologic mediators of he-
mostasis, as do the tick histamine-binding proteins (32) or
lipocalins of Rhodnius prolixus (33, 34). PpSP32 is similar to
a silk protein from Nephila clavipes. PpSP42 and PpSP44 are
similar to the Yellow-B protein from Drosophila melano-
gaster with unknown function and to the major royal jelly
protein from Apis mellifera. Because P. papatasi produces an
intense DTH reaction and this reaction enhances its feed-
Figure 9. Humoral response and DTH reaction on B /  and wt mice
after vaccination with SP15-Pl. Western blots showing antibody reactiv-
ity of wt but not B /  mice against P. papatasi salivary homogenates (A).
Measurements indicated the millimetric difference between the ear chal-
lenged with SGH and the noninoculated ear, on B /  and wt C57BL/10
mice vaccinated with SP15-Pl (B). Mice were immunized twice in the
right ear (2-wk intervals) or not with 5  g of SP15-Pl or CTL-Pl and
challenged in the left ear 2 wk after the last immunization with 500 L.
major promastigotes in the presence of 0.5 pairs of SGH. 24 h after inocu-
lation, the ear thickness was measured and the difference between the ear
thickness before challenge and 24 h after challenge was computed. Sym-
bols and bars represent mean thickness in mm   SE; five mice per group.
Figure 10. Role of DTH in mouse immunization with SP15-Pl on
subsequent  L. major infection. B /  mice ( ,   ) and their controls
(C57BL/10, wt;  ,  ), were immunized twice in the right ear (2-wk in-
terval) with the VR1020 plasmid with (filled symbols) or without (open
symbols), the SP15 sequence and challenged 2 wk later in the left ear with
L. major promastigotes in combination with 0.5 pairs of homogenized P.
papatasi salivary glands. (A) Lesion size progression. (B) Parasite numbers
recovered from the lesion at 5.5 wk. Each number and bar represents the
average   SE of five mice. (*) indicates significance at P   0.05 when the
number of parasites on the SP15-Pl group was compared with the con-
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ing success (19), it may be possible that some or several of
these molecules have been selected for inducing this im-
mune reaction in their hosts.
In this study, we used self-healing C57BL/6 mice, a rel-
evant model of L. major vaccination on subsequent Leish-
mania infection. This system provides a challenge model
that more closely reproduces the pathology and immunity
associated with natural infection (15, 19). When used as an
immunogen, the SDS-PAGE band containing SP15 was
efficient in providing immunity against leishmaniasis when
parasites were coinoculated with SGH. After DNA vacci-
nation with SP15, mice produced high titer of anti SP15
antibodies and developed a strong DTH in response to sand
fly bites, comparable with the one described previously us-
ing salivary extract as immunogen. Mice vaccinated with
the SP15 plasmid and challenged with parasites plus SGH
were efficiently protected against the manifestations of the
disease at the site of the inoculation. The protection
achieved using SP15 DNA vaccination was long lasting.
The fact that both the pathology and the number of para-
sites were significantly reduced compared not only with
appropriate controls but also with mice inoculated with the
parasite alone suggests that the observed protection resulted
not only from a neutralization of the SGH effect(s) but had
an additional effect on the ulterior parasite survival. SP15 is
one of the salivary antigens recognized by people naturally
exposed in endemic areas of L. major (unpublished data).
Additionally, this molecule is in the range of the candidates
able to induce a strong DTH in response to SGH in the ex-
perimental mouse model (19). Together, these results vali-
date the use of SP15 as a candidate vaccine against L. major
infection.
The fact that B /  mice that lack B lymphocytes and
cannot produce antibodies were also efficiently protected
when vaccinated with the SP15-Pl plasmid and challenged
with L. major plus SGH indicates that the cellular response
to SP15 is sufficient to confer protection against L. major.
We cannot exclude, however, the participation of antibod-
ies on the protective effect of the vaccine on the wt mice.
Additionally, B /  mice had fewer parasites and less pa-
thology than did wt mice. This is in accordance with the
effective immunity of B /  mice against L. donovani (35),
and with anti-parasite IgG-enhancing parasite uptake by
macrophages (36). These results suggest, as proposed before
(18, 19), that the DTH response to sand fly antigens is re-
sponsible for the anti-Leishmania immunity conferred by
sand fly homogenate or sand fly bite immunization.
Several nonexclusive mechanisms may explain the effi-
ciency of the anti-SP15 vaccine against Leishmania major in-
fection, in the context of the DTH reaction that it induces,
as follows: we recently described (37) that the infection by
L. major is characterized by an initial silent phase lasting 4–5
wk, at which time a large dermal load of parasites is estab-
lished. This silent-growth phase is characterized by the ab-
sence of lesion formation, or any overt histopathologic
changes in the site. We propose that the inoculation of par-
asites in the context of DTH response may not favor the
establishment of the homeostatic state necessary for the op-
timal growth of the parasite. The presence at the site of the
DTH of IFN-  or other inflammatory cytokine may in-
duce a direct initial killing of the parasite. The DTH at the
site may act as an adjuvant of the anti-Leishmania response.
The anti-Leishmania lymphocytes will be primed in the
context of a proinflammatory milieu leading to the poten-
tial generation of a stronger Th1 response. The mechanism
by which the SP15 DNA vaccine and the sand fly bite pro-
tection occur could be similar. Indeed, we showed a rapid
increase of the level of IFN-  and IL-12 at the site of the
rechallenge in mice presensitized by the bite of an unin-
fected vector (18). Finally, it is possible that lymphocytes
attracted to the DTH site contain large amounts of adeno-
sine deaminase (38) that could degrade salivary adenosine
to inosine. We think this hypothesis unlikely because these
lymphocytes should be attracted maximally several hours
after saliva injection—when adenosine might have diluted
out of the site—and because the product of adenosine
deaminase, inosine, also has potent immunomodulatory
properties (39).
We used SGH coinoculated with parasites as a surrogate
for sand fly transmission. Validation of this method has re-
cently been provided in which immunity to P. papatasi
sand fly bites was found effective against sand fly transmis-
sion of L. major parasites (18). Additionally, we show that
mouse immunity to P. papatasi antigens is similarly ac-
quired by sand fly bite or SGH inoculation (Fig. 1), and
that vaccination with SP15-Pl induces a DTH response af-
ter sand fly bites (Fig. 6). Unfortunately, the rearing of in-
fected sand flies for challenge studies is not presently an
easily reproducible methodology. Perhaps vaccine ef-
fectiveness studies for L. major and other Leishmania/vec-
tor associations could be conducted more appropriately
with vaccinated rodents or dogs in endemic zones, after de-
fining vaccine candidates by needle challenge of parasites
co-inoculated or not with SGH.
There exist presently a number of vaccine candidates to
prevent leishmaniasis, based on the GP63 (40), Leishmania
homologue of receptors for activated C kinase (LACK)
(41, 42), and promastigote surface antigen (PSA)-2 (43) an-
tigens. None of these studies takes into account the dra-
matic effects of saliva. No study includes parasite challenge
in the presence of vector saliva. Therefore, the possibility
remains that even in the most efficient vaccination protocol
described (42, 44), the adjunction of the saliva will coun-
teract the efficiency of the vaccine. The use of an antisaliva
vaccine, alone or in combination with anti-Leishmania vac-
cine, may allow the host exposed to the bite of infected
sand flies to develop minor or no pathology and a strong
anti-Leishmania immunity.
Although SP15 appeared to be the best vaccine candi-
date after our SDS-PAGE fractionation of SGH, it is possi-
ble that other salivary proteins could confer similar protec-
tion in the same mice, or that other proteins could be more
effective in mice of different immunogenetic background.
Indeed, we observed previously that different HPLC frac-341 Valenzuela et al.
tions from SGH produced strong DTH response in mice of
either BALB/c or C57BL/6 backgrounds (19). Most sali-
vary proteins of P. papatasi are now available to test these
hypotheses. It should also be noted that there is the possi-
bility of using the recombinant salivary proteins described
in this paper for epidemiologic investigations of the effect
of human natural immunity against these immunogens and
its impact on disease outcome, as is being done with L. lon-
gipalpis–transmitted leishmaniasis in Brazil (45)
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